Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of topical ruxolitinib cream for atopic dermatitis in China
ChiCTR2400084289Phase 3Not yet recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in atopic dermatitis (AD) (2 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Proportion of participants achieving IGA-TS at Week 8. Planned start May 2024; status: not yet recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2400084289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084289.